This article was originally published Dec. 30.

Building on last year's trend of numerous mergers and acquisitions within the next-generation sequencing market, in 2013, the space was again marked more by business deals and less by sequencing technology breakthroughs.

Sequencing companies sought to gain an edge over the competition through license agreements, mergers, and acquisitions — particularly those that focused on clinical applications — while companies outside of the next-gen space sought to get in on the sequencing game.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Browse our free articles
You can still register for access to our free content.

In PLOS this week: genes under positive selection in Plasmodium falciparum populations, genetic variation in Epstein-Barr viruses, and more.

Cancer clinical trial patients settle with Anil Potti and Duke University.

A trio of researchers is trying to raise money to sequence and analyze the genome of a cat with a suite of unusual traits.

Two Johns Hopkins researchers discuss the need for evidence-based data analysis.